H

HLB Inc
KOSDAQ:028300

Watchlist Manager
HLB Inc
KOSDAQ:028300
Watchlist
Price: 75 400 KRW 2.86% Market Closed
Market Cap: 9.9T KRW
Have any thoughts about
HLB Inc?
Write Note

Gross Margin
HLB Inc

14.9%
Current
22%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
14.9%
=
Gross Profit
7.7B
/
Revenue
51.9B

Gross Margin Across Competitors

Country KR
Market Cap 9.9T KRW
Gross Margin
15%
Country JP
Market Cap 6.8T JPY
Gross Margin
86%
Country CH
Market Cap 37.9B CHF
Gross Margin
55%
Country DK
Market Cap 200.9B DKK
Gross Margin
68%
Country US
Market Cap 16.9B USD
Gross Margin
70%
Country CA
Market Cap 6.9B USD
Gross Margin
61%
Country CN
Market Cap 48.6B CNY
Gross Margin
73%
Country US
Market Cap 6.3B USD
Gross Margin
65%
Country US
Market Cap 6.1B USD
Gross Margin
47%
Country UK
Market Cap 4.8B GBP
Gross Margin
56%
Country CH
Market Cap 4.9B CHF
Gross Margin
35%
No Stocks Found

HLB Inc
Glance View

Market Cap
9.9T KRW
Industry
Health Care

HLB Inc. is a dynamic biopharmaceutical company dedicated to the discovery and development of innovative treatments for a range of serious diseases. Founded on the principles of scientific excellence and a commitment to patient care, HLB has quickly gained recognition for its robust portfolio of drug candidates targeting areas such as oncology, autoimmune diseases, and rare disorders. The company's strategic approach combines cutting-edge research with advanced clinical trials, leveraging partnerships with leading research institutions and healthcare organizations to propel its therapeutic innovations. With a strong financial backing and a clear vision for growth, HLB is not just about developing drugs; it’s about transforming patient outcomes and making a meaningful impact on global health. As an investor, HLB Inc. presents a compelling opportunity anchored in its core strengths: a seasoned management team with a proven track record, a rich pipeline of promising drug candidates, and a robust intellectual property portfolio that secures its market position. The company’s commitment to transparency and strategic operational decisions positions it well for sustainable growth in the competitive biopharmaceutical landscape. With the increasing demand for effective therapies and advancements in medical technology, HLB stands poised to unlock significant shareholder value while driving progress in medical treatment options. This compelling narrative of potential, combined with HLB's dedication to innovation, makes it an intriguing prospect for investors seeking exposure to the biopharmaceutical sector.

Intrinsic Value
880.61 KRW
Overvaluation 99%
Intrinsic Value
Price
H

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
14.9%
=
Gross Profit
7.7B
/
Revenue
51.9B
What is the Gross Margin of HLB Inc?

Based on HLB Inc's most recent financial statements, the company has Gross Margin of 14.9%.